39 results on '"Brys, Reginald"'
Search Results
2. Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases
3. Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312
4. Discovery and development of ASK1 inhibitors
5. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
6. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
7. Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312
8. ESDR350 - IRAK4 drives pathogenic processes in inflammatory skin diseases
9. Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases
10. Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis
11. Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial
12. The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
13. The α7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation
14. Correction to Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors
15. Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors
16. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis
17. Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors
18. Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF
19. Sa1844 The JAK1-Selective Inhibitor, Filgotinib, Reverses the Disease Signature of Colon Mucosa in Experimental Colitis
20. Adenoviral vectors expressing siRNAs for discovery and validation of gene function
21. Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis
22. Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
23. Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic
24. Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
25. Abstract 1753: GLPG1790: The first Ephrin (EPH) receptor tyrosine kinase inhibitor for the treatment of triple negative breast cancer
26. 188 Exploration of GLPG0634, the First Selective JAK1 Inhibitor, in Inflammatory Bowel Disease Is Supported by Early Clinical Results and Mouse DSS-Colitis Data
27. Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
28. A multiparameter approach to monitor disease activity in collagen-induced arthritis
29. The α7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation
30. Triazolopyridines as SelectiveJAK1 Inhibitors: FromHit Identification to GLPG0634.
31. Arrayed adenoviral expression libraries for functional screening
32. Oct-1 Is Involved in the Transcriptional Repression of the von Willebrand Factor Gene Promoter
33. Identicalcis-Acting Elements and Relatedtrans-Acting Factors Control Activity of Nonviral Promoter inSchizosaccharomyces pombeand Mammalian Cells
34. Identical cis-Acting Elements and Related trans-Acting Factors Control Activity of Nonviral Promoter in Schizosaccharomyces pombe and Mammalian Cells.
35. Three classes of mammalian transcription activation domain stimulate transcription in Schizosaccharomyces pombe.
36. A novel expression cloning method to isolate mammalian transcription factors in Schizosaccharomyces pombe.
37. Corrigendum: Arrayed adenoviral expression libraries for functional screening.
38. Discovery of 9-Cyclopropylethynyl-2-(( S )-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1- a ]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.
39. The alpha7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.